SEC Form 4 · accession 0001178913-26-004371
Chemomab Therapeutics Ltd. · CMMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Harris Cohen
Director
Period of report
Aug 27, 2026
Accepted (ET)
Sep 1, 2026 · 10:05 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534248
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary Shares | Aug 27, 2026 | S | 1,304 | $2.85 | D | 34,000 | D | |
| American Depositary Shares | Aug 28, 2026 | S | 1,000 | $2.80 | D | 33,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy American Depositary Shares)F1 | $52.80 | Jul 16, 2020 | A | 172 | A | — | Jul 16, 2030 | American Depositary Shares | 172 | 172 | D |
| Stock option (right to buy American Depositary Shares)F2 | $109.04 | Apr 19, 2021 | A | 2,971 | A | — | Apr 19, 2031 | American Depositary Shares | 2,971 | 3,143 | D |
| Stock option (right to buy American Depositary Shares)F3 | $14.12 | Mar 7, 2022 | A | 1,705 | A | — | Mar 7, 2032 | American Depositary Shares | 1,705 | 4,848 | D |
| Stock option (right to buy American Depositary Shares)F4 | $6.48 | Mar 21, 2023 | A | 1,714 | A | — | Mar 21, 2033 | American Depositary Shares | 1,714 | 6,562 | D |
| Stock option (right to buy American Depositary Shares)F5 | $2.96 | Mar 18, 2024 | A | 2,520 | A | — | Mar 18, 2034 | American Depositary Shares | 2,520 | 9,082 | D |
| Stock option (right to buy American Depositary Shares)F6 | $6.16 | Mar 16, 2025 | A | 3,821 | A | — | Mar 16, 2035 | American Depositary Shares | 3,821 | 12,903 | D |
| Stock option (right to buy American Depositary Shares) | $2.14 | Mar 16, 2026 | A | 5,172 | A | Mar 16, 2027 | Mar 16, 2036 | American Depositary Shares | 5,172 | 18,075 | D |
Explanation of responses
- F1The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.
- F2The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
- F3The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
- F4The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
- F5The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
- F6The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.